Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fundación de investigación HM
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
University of Florida
Jonsson Comprehensive Cancer Center
Institut Bergonié
Advenchen Laboratories, LLC
USWM, LLC (dba US WorldMeds)
Takara Bio Inc.
USWM, LLC (dba US WorldMeds)
USWM, LLC (dba US WorldMeds)
Oslo University Hospital
Oslo University Hospital
Baylor College of Medicine
Immatics US, Inc.
University Health Network, Toronto
Northwestern University
Seattle Children's Hospital
Seattle Children's Hospital
Ipsen
Hadassah Medical Organization
City of Hope Medical Center
Valo Therapeutics Oy
HRYZ Biotech Co.
Daiichi Sankyo
Essen Biotech
Ipsen
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Columbia University
Foghorn Therapeutics Inc.
Ipsen
University Hospital Heidelberg
Medigene AG
C4 Therapeutics, Inc.
University Hospital Tuebingen
Takara Bio Inc.
Ipsen
Sumitomo Pharma America, Inc.
Grupo Espanol de Investigacion en Sarcomas
Eastern Cooperative Oncology Group
Fred Hutchinson Cancer Center
OncoTherapy Science, Inc.
Adaptimmune
Washington University School of Medicine
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eli Lilly and Company